Over the course of the reformulation program, tesa Labtec produced over 200 different variants of the TPM®/Oxymorphone patch to ensure they identified the optimal composition. The most promising of these new TPM®/Oxymorphone patches has increased transdermal flux in-vitro compared to the previous clinical patch, as well as enhanced physical and chemical stability across a range of standard stress tests. The performance of the patch in these assessments met or exceeded Phosphagenics’ expectations towards a commercial product. Importantly, the reformulation program produced TPM®/Oxymorphone patches appropriate for commercialisation in either the Japanese or US market. These TPM®/Oxymorphone patches have now been submitted for final stability assessments.
the jap 1 day patch didn't cut the mustard, but the 72 hr patch is set to go...a good payout from mylan may see us embark on a ph 2...if a US partner cant be found
Over the course of the reformulation program, tesa Labtec...
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.923M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 35 | 43869108 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 44263580 | 22 |
View Market Depth
| Last trade - 16.12pm 04/10/2024 (20 minute delay) ? |
| AVE (ASX) Chart |
Day chart unavailable